Trial
NCT02678143
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Alemtuzumab
Why stopped
Closed early due to competing studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-14